intrauterine devices market

The intrauterine Devices Market By Type (Hormonal Intrauterine and Copper Intrauterine), End-User (Hospitals, Gynaecology Clinics, and Community Health Care Centres), and Geography is expected to grow at a steady CAGR forecast till 2030 owing to an increase in awareness in family planning and high rates of unintended pregnancies.

The global intrauterine devices market was valued at USD 4.85 billion in 2023, growing at a CAGR of 5.81% during the forecast period from 2024 to 2030 to reach USD 6.77 billion by 2030. The intrauterine devices market is witnessing positive market growth owing to the factors such as increasing awareness about family planning, high rates of unintended pregnancies, and various healthcare initiatives by the government around contraception, which are contributing to the growth of the intrauterine devices market during forecast period from 2024-2030.

Intrauterine Devices Market Dynamics:

One of the main drivers of the intrauterine devices (IUDs) market is the increasing awareness about family planning. In November 2020, World Health Organization (WHO) released worldwide data on contraceptive methods that in 2019, 1.1 billion women of reproductive age (15-49) need family planning, of whom 842 million use contraceptive methods, and 270 million have unmet needs for contraception.

Family planning is a choice of most parents these days which demands the need for contraceptives to delay pregnancies or limit the number of children, since IUDs are better than other contraceptive methods as they are 99% effective and provide long-term protection against pregnancy. Therefore, an increase in contraceptive demand will increase the demand for IUDs, thereby propelling the growth of the intrauterine devices market in the forecast period (2024-2030).

Moreover, another key factor that may be responsible for the rise in the intrauterine devices market is the high rates of unintended pregnancies. Around the globe in low and middle-income countries, 74 million women have unintended pregnancies annually resulting in 25 million abortions and 47000 maternal deaths each year.

Additionally, according to the WHO in November 2021, worldwide approximately 6 in 10 unintended pregnancies resulted in induced abortion from which 45% of abortions are unsafe, and can lead to the death of the mother. Worldwide each year approximately 73 million induced abortions take place. Each year 4.7-13.2% of maternal deaths take place due to unsafe abortions, and nearly 220 maternal death per 100,000 happens in developing region. Therefore, to overcome maternal deaths, contraceptives such as IUDs should be used which can reduce unintended pregnancies.

Thus, the use of IUDs can help women with family planning concerns to prevent unintended pregnancies, unsafe abortions, and maternal deaths. Therefore, because of the above-mentioned factors, an increase in the IUD market will be seen in the forecast period.

However, intrauterine devices can cause serious health issues such as infection, bleeding, and pain, among others moreover, it does not protect against sexually transmitted diseases (STDs), thus this becomes challenging which can slow down the intrauterine devices market growth.

Intrauterine Devices Market Segment Analysis:

Intrauterine Devices Market By Type (Hormonal Intrauterine and Copper Intrauterine), End-User Type (Hospitals, Gynecology Clinics, and Community Health Care Centers), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the type segment of the IUDs market, hormonal intrauterine is estimated to hold the highest market share during the forecast period (2024-2030).

The wide application and the various advantages associated with the use of hormonal intrauterine devices, and product development activities such as recent launches and approvals are expected to bolster the market demand for hormonal intrauterine devices in the forthcoming years.

According to data by Family Planning NSW, hormonal IUDs are found to have an edge over copper intrauterine devices in terms of efficiency where they provide 99.8% efficiency over copper IUDs, which provide 99.2% efficiency. 

Hormonal IUDs are preferred more in general as they have been found to help women reduce menstrual bleeding, reduce menstrual pain, reduce the risk, and slow down the growth of uterine fibroids due to the effect of the hormone progesterone.

Along with this, hormonal IUDs are very convenient, easy to use, and cost-effective, without any feeling of entanglement or inconvenience.

In addition, in August 2021, Bayer AG announced that the US Food and Drug Administration (FDA) approved a Supplemental New Drug Application (sNDA) to extend the life span of the Mirena IUD.

In October 2019, US FDA approved Medicines360's LILETTA, an alevonorgestrel-releasing intrauterine system of 52 mg that can prevent pregnancy for up to six years.

Thus, the interplay of all the above-mentioned factors is likely to expand the market for hormonal intrauterine devices during the forecast period from 2024-2030.

North America is expected to dominate the overall Intrauterine Devices:

Among all the regions, North America is expected to account for the largest share of global intrauterine devices.

Significant factors such as the increased shift towards planned or delayed pregnancies, and government initiatives towards improving family planning awareness, among others are all contributing to the growth of the intrauterine devices market in the region.

The tendency of planned pregnancies has increased due to increasing female employment, additional education of women leading to awareness, and other medical reasons can be the factors responsible for planned/delayed pregnancies.

Therefore, the use of contraceptive methods such as IUDs by women can be expected to increase in the coming years as they are found to be safe, and are a preferred way to delay pregnancies for a long period.

Moreover, governmental initiatives such as those by the collaboration of the Pan American Health Organization (PAHO), United Nations Population Fund (UNPFA), and WHO, in October 2020, conducted an adolescent pregnancy prevention week from 18th October – 24th October 2020. The initiatives hosted several webinars, and technical meetings on adolescent pregnancy prevention and risks related to it in the Caribbean.

Thus, factors such as planned and delayed pregnancies, along with the healthcare initiatives in the US by government bodies help people to understand the risks related to unintended pregnancies and the advantages of family planning, ultimately helping in population growth control.

Hence, the interplay of all the above-mentioned factors will augment the intrauterine devices market growth in the country during the forecasted period from 2024-2030.

Intrauterine Devices Market Key Players:

Some of the key market players operating in the intrauterine devices market include CooperSurgical Inc, Bayer AG, Odyssea Pharma SPRL, Merck & Co Inc, Allergan Inc, EUROGINE S.L, OCON Medical Ltd, HLL Lifecare Limited, Mona Lisa, Prosan International BV, SMB Corporation of India, Medicines360, AbbVie Inc, Teva Pharmaceutical Industries Ltd, Pregna International Limited, HRA Pharma, Melbea Innovations, Mylan N.V, Meril Life Sciences Pvt. Ltd, among others.

Recent Developmental Activities in the Intrauterine Devices:

• In February 2025, Sebela Women's Health Inc., a division of Sebela Pharmaceuticals, announced FDA approval of MIUDELLA® (copper intrauterine system) for pregnancy prevention in women of reproductive potential for up to three years. MIUDELLA is a hormone-free, low-dose copper IUD, the first FDA-approved in the U.S. in over 40 years.
• In October 2021, Bayer announced to invest of €400 million to expand access to modern contraception.
• In December 2020, to assist the US launch of Intrauterine Ball (IUB), Ballerine Rhia Ventures invested in Israeli-based OCON Healthcare.
• In August 2021, the launch of the Avibela hormonal intrauterine device in Kenya was announced by Medicines360, MSI Reproductive Choices, and MSK.

Key Takeaways from the Intrauterine Devices Market Report Study

• Market size analysis for current Intrauterine Devices Market size (2023), and market forecast for 5 years (2024-2030)
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global intrauterine devices.
• Various opportunities are available for the other competitor in the intrauterine devices market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current intrauterine devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for intrauterine devices market growth in the coming future?

Target Audience who can be benefited from this Intrauterine Devices Market Report Study

• Intrauterine Devices products providers
• Research organizations and consulting companies
• Intrauterine Devices -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in intrauterine devices
• Various End-users who want to know more about the intrauterine devices market and the latest technological developments in intrauterine devices.

Frequently Asked Questions for Intrauterine Devices:

1. What are intrauterine devices?

Intrauterine devices are small devices that are inserted inside the womb (uterus) of women by doctors to prevent pregnancies, which give protection against pregnancy for 5-10 years. These are one form of long-acting reversible birth control.

2. What is the market for global intrauterine devices?

The global intrauterine devices market was valued at USD 4.85 billion in 2023, growing at a CAGR of 5.81% during the forecast period from 2024 to 2030 to reach USD 6.77 billion by 2030.

3. What are the drivers for the global intrauterine devices market?

The intrauterine devices market is witnessing positive market growth owing to the factors such as family planning, increased tendency for planned delayed pregnancies, high rates of unintended pregnancies, and healthcare initiatives by the government.

4. Who are the key players operating in the intrauterine devices market?

Some of the key market players operating in the global intrauterine devices market include CooperSurgical Inc, Bayer AG, Odyssea Pharma SPRL, Merck & Co Inc, Allergan Inc, EUROGINE S.L, OCON Medical Ltd, HLL Lifecare Limited, Mona Lisa, Prosan International BV, SMB Corporation of India, Medicines360, AbbVie Inc, Teva Pharmaceutical Industries Ltd, Pregna International Limited, HRA Pharma, Melbea Innovations, Mylan N.V, Meril Life Sciences Pvt. Ltd, among others.

5. Which region has the highest share in the global intrauterine devices market?

North America is expected to hold the highest share in the revenue of the intrauterine devices market during the forecast period. High abortion rates, healthcare initiatives by the government for family planning and to prevent unintended pregnancies will increase the demand for intrauterine devices in North America leading to a rise in the overall intrauterine devices market growth in this region.